Logo for Faron Pharmaceuticals

Faron Pharmaceuticals Investor Relations Material

Latest events

Logo for Faron Pharmaceuticals

Study Update

Faron Pharmaceuticals
Logo for Faron Pharmaceuticals

Study Update

10 Dec, 2024
Logo for Faron Pharmaceuticals

CMD 2024

22 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Faron Pharmaceuticals

Access all reports
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. It focuses on the discovery and development of anti-scarring drugs, immunotherapy treatments, and cancer vaccines. The company’s product pipeline includes Traumakine, which is used in the treatment of acute respiratory distress syndrome; Clevegen that targets the programmed cell death 1/programmed cell death ligand 1 pathway involved in tumor growth and suppression; and preclinical stage product candidates, such as Apograft for the treatment of solid tumors. Faron Pharmaceuticals Oy was founded in 2000 and is headquartered in Turku, Finland.